Pimavanserin Market

Pimavanserin Market Size, Share & Industry Analysis, By Source (Chemical Synthesis, Contract Manufacturing [CDMO-Based Synthesis], Multi-Step Organic Intermediates, Fermentation-Derived Precursors, Hybrid Synthesis [Synthetic + Biological]), By End-User Industry (Pharmaceuticals, Neurology & Psychiatry Clinics, Hospitals & Mental Health Institutions, Contract Manufacturing Organizations, Research & Development Institutes), and Forecast, 2025–2035

The global Pimavanserin market is projected to grow at a CAGR of 7.3% during the forecast period, driven by its expanding application in the treatment of Hepatitis C Virus (HCV) across genotypes 1–6. The rise in demand for fixed-dose antiviral combinations, especially with Glecaprevir, is significantly contributing to market expansion. Regulatory approvals and inclusion in global HCV treatment guidelines are accelerating adoption in both developed and developing healthcare systems.

Geographically, North America currently leads the market due to high diagnosis and treatment rates, robust healthcare infrastructure, and presence of major pharmaceutical manufacturers. However, the Asia-Pacific region is anticipated to witness the fastest growth, driven by increasing HCV prevalence, government-led awareness programs, and improved access to antiviral therapies in countries like India and China. Europe also remains a strong market, bolstered by universal healthcare coverage and high adoption of direct-acting antivirals.

The Pimavanserin API market report provides an in-depth analysis of regulatory pathways, patent landscapes, pricing dynamics, and formulation trends. Its use in combination therapies for chronic HCV—including co-infected HIV-HCV patients and those with compensated cirrhosis—positions it as a critical component in global antiviral strategies.

Seeking Comprehensive Intelligence on Different markets? Get in Touch with our Experts

Report Scope & Segmentation

  1. Introduction
  • Overview of Pimavanserin
  • Key End-Users & Industry Use Cases
  • Market Scope & Study Objectives
  1. Market Overview
  • Global Market Size & Growth Trends (Historical & Forecast)
  • Demand-Supply Dynamics
  1. Segmental Outlook
  • By Source
    • Chemical Synthesis
    • Multi-Step Organic Intermediates
    • Fermentation-Derived Precursors
  • Key End-User Industry
  • Pharmaceuticals
  • Neurology & Psychiatry Clinics
  • Hospitals & Mental Health Institutions
  • Research & Development Institutes

 

  1. Price Analysis
  • Current Price Trends (Per kg & Per Ton)
  • Price Fluctuation Factors (Raw Material Costs, Production, Trade Tariffs)
  • Regional Price Comparison (North America, Europe, Asia-Pacific, and Other)
  1. Trade Analysis
  • Major Exporting & Importing Countries
  • Trade Volume & Value Statistics
  • Impact of Trade Regulations & Policies
  1. Regional Analysis
  • North America (US and Canada)
  • Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, Taiwan, India, and Rest of Asia-Pacific)
  • Rest of the World (Latin America, and Middle East, and Africa)
  1. Competitive Landscape
  • Top Global Manufacturers & Production Capacity
  • Company Profiles & Key Developments
    • ACADIA Pharmaceuticals Inc.
    • Cipla Ltd.
    • Jubilant Ingrevia Ltd.
    • LGM Pharma
    • Amneal Pharmaceuticals
    • Clearsynth Labs Ltd.
    • SimSon Pharma Limited
    • Chemkart
    • Angene International Limited
    • TCI Chemicals Pvt. Ltd.
    • Hangzhou FandaChem Co., Ltd.
    • Boc Sciences
    • Shanghai Pharma
    • Wuhan Fortuna Chemical Co., Ltd.
    • Manus Aktteva Biopharma LLP
    • Alchem International Pvt. Ltd.
    • Suven Pharmaceuticals
    • Aarti Drugs Ltd.
    • Sai Life Sciences
    • Laurus Labs
  • Mergers, Acquisitions & Investments
  1. Regulatory & Compliance Factors
  • FDA, REACH, and Other Regulatory Frameworks
  • Environmental & Safety Considerations
  • Emerging Policies Impacting Market Growth
  1. Conclusion & Strategic Recommendations
  • Key Takeaways for Stakeholders
  • Market Entry Strategies
What is a Pimavanserin?
Pimavanserin is a selective serotonin inverse agonist targeting 5-HT2A receptors, primarily used to treat Parkinson’s disease psychosis. It is distinct from traditional antipsychotics as it avoids dopaminergic pathways, thereby reducing the risk of motor side effects.
What is the market size for Pimavanserin?
The Pimavanserin market is expanding at a CAGR of 6.4% during the forecast period from 2025 to 2035. Growth is driven by rising neurodegenerative disorders and demand for safer, targeted antipsychotic treatments.
What are the drivers for the Pimavanserin Market?
Key drivers include the increasing incidence of Parkinson’s and Alzheimer’s-related psychosis, demand for non-dopaminergic therapies, ongoing clinical trials for broader indications, and favorable regulatory designations like orphan drug status.
Who are the key players operating in the Pimavanserin Market?
Major players include ACADIA Pharmaceuticals, Cipla, Jubilant Ingrevia, Amneal Pharmaceuticals, Clearsynth Labs, LGM Pharma, and Boc Sciences.
Which region would exhibit the fastest growth in the Pimavanserin Market?
The Asia-Pacific region is expected to experience the fastest growth due to increasing aging populations, rising awareness of mental health conditions, and expansion of neuroscience research in countries like China, India, and Japan.
$1800/- Single User License
$3600/- Multi User License

How can we help you?

Reach out to discuss how our team can help your business achieve real results.